These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 28163004)

  • 1. Intermittent sunitinib for metastatic renal cell carcinoma.
    Venkatesan P
    Lancet Oncol; 2017 Mar; 18(3):e139. PubMed ID: 28163004
    [No Abstract]   [Full Text] [Related]  

  • 2. [News on ASCO 2007. Sunitinib in the treatment of metastatic renal carcinoma and gastrointestinal stromal tumors].
    Mansueto G; Longo F
    Tumori; 2007; 93(5):Suppl 1-16. PubMed ID: 18038894
    [No Abstract]   [Full Text] [Related]  

  • 3. Dose matters: the importance of appropriate dosing: a case report on sunitinib treatment in a patient with metastatic renal cell carcinoma.
    Bojic M; Schmidinger M
    Clin Genitourin Cancer; 2012 Dec; 10(4):277-9. PubMed ID: 22658385
    [No Abstract]   [Full Text] [Related]  

  • 4. Phase III study of sunitinib malate (SU11248) versus interferon-alpha as first-line treatment in patients with metastatic renal cell carcinoma.
    Reddy K
    Clin Genitourin Cancer; 2006 Jun; 5(1):23-5. PubMed ID: 16859575
    [No Abstract]   [Full Text] [Related]  

  • 5. Sunitinib for metastatic renal cell carcinoma.
    Mukherji D; Larkin J; Pickering L
    Future Oncol; 2010 Sep; 6(9):1377-85. PubMed ID: 20919823
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term response with sunitinib for metastatic renal cell carcinoma.
    Ronnen EA; Kondagunta GV; Ginsberg MS; Russo P; Motzer RJ
    Urology; 2006 Sep; 68(3):672.e19-20. PubMed ID: 16979716
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intermittent treatment with sunitinib may achieve complete response in metastatic renal cell carcinoma.
    Aksu G; Ensaroglu F; Dolasik I; Temiz S; Halis H; Sener SY; Kaya A; Uygun K
    J BUON; 2010; 15(4):798-9. PubMed ID: 21229650
    [No Abstract]   [Full Text] [Related]  

  • 8. [Use of sunitinib in metastatic renal cell carcinoma patients with poor prognosis].
    Timofeev IV; Demidov LV; Petenko NN
    Vopr Onkol; 2011; 57(1):50-4. PubMed ID: 21598708
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Improvement of psoriasis during sunitinib therapy for renal cell carcinoma.
    Narayanan S; Callis-Duffin K; Batten J; Agarwal N
    Am J Med Sci; 2010 Jun; 339(6):580-1. PubMed ID: 20421784
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Second-line treatment for renal cell cancer.
    Di Lorenzo G; De Placido S; Buonerba C
    Br J Cancer; 2012 Feb; 106(4):617-8. PubMed ID: 22333706
    [No Abstract]   [Full Text] [Related]  

  • 11. Temsirolimus for advanced renal-cell carcinoma.
    Fazio N; Dettori M; Lorizzo K
    N Engl J Med; 2007 Sep; 357(10):1050; author reply 1050-1. PubMed ID: 17804854
    [No Abstract]   [Full Text] [Related]  

  • 12. [Sunitinib versus interferon-alpha in metastatic renal-cell carcinoma].
    Irani J
    Prog Urol; 2007 Sep; 17(5):996. PubMed ID: 17969805
    [No Abstract]   [Full Text] [Related]  

  • 13. Metastatic mucinous tubular and spindle cell carcinoma of the kidney responding to sunitinib.
    Larkin J; Fisher R; Pickering L; Thway K; Livni N; Fisher C; Gore M
    J Clin Oncol; 2010 Oct; 28(28):e539-40. PubMed ID: 20679595
    [No Abstract]   [Full Text] [Related]  

  • 14. Complete cerebral response with sunitinib for metastatic renal cell carcinoma.
    Medioni J; Cojocarasu O; Belcaceres JL; Halimi P; Oudard S
    Ann Oncol; 2007 Jul; 18(7):1282-3. PubMed ID: 17675397
    [No Abstract]   [Full Text] [Related]  

  • 15. Alternate sunitinib schedules in patients with metastatic renal cell carcinoma.
    Kalra S; Rini BI; Jonasch E
    Ann Oncol; 2015 Jul; 26(7):1300-4. PubMed ID: 25628443
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 'Sunitinib withdrawal phenomenon' or spontaneous regression in renal cell cancer.
    Rothermundt CA; Omlin A; Gillessen S
    Ann Oncol; 2009 Jun; 20(6):1144-6. PubMed ID: 19465428
    [No Abstract]   [Full Text] [Related]  

  • 17. Improvement of actinic keratosis associated with sunitinib therapy for metastatic renal cell carcinoma.
    Mir-Bonafé JM; Cañueto J; Bravo J; de Unamuno P
    Int J Dermatol; 2013 Nov; 52(11):1445-7. PubMed ID: 23432117
    [No Abstract]   [Full Text] [Related]  

  • 18. Prostatic metastasis of renal cell carcinoma successfully treated with sunitinib.
    Fokt RM; Templeton A; Gillessen S; Ohlschlegel C; Schmid HP
    Urol Int; 2009; 83(1):122-4. PubMed ID: 19641373
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recent aspects of sunitinib therapy in patients with metastatic clear-cell renal cell carcinoma: a systematic review of the literature.
    Minardi D; Quaresima L; Santoni M; Bianconi M; Scartozzi M; Cascinu S; Muzzonigro G
    Curr Urol Rep; 2015 Feb; 16(2):3. PubMed ID: 25627021
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Consolidative renal cell carcinoma metastatectomy for partial response after multitargeted tyrosine kinase inhibitor therapy.
    Neill MG; Wei AC; Jewett MA
    Urology; 2007 Jul; 70(1):178.e9-11. PubMed ID: 17656238
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.